Higher Female TSH Associated With Lower Mannan-Binding Lectin
|
By LabMedica International staff writers Posted on 15 Jan 2020 |

Image: Synergy H1 Hybrid Multi-Mode Reader is a configurable microplate reader (Photo courtesy of BioTek)
Mannan-binding lectin (MBL) is a main component of the lectin pathway of the complement system. Lower MBL levels are associated with, among other conditions, hypothyroidism and adverse pregnancy outcomes.
In turn, adverse pregnancy outcomes and infertility may result from hypothyroidism, even in patients with high normal thyroid-stimulating hormone (TSH). An increased MBL blood level was found in hyperthyroid patients while decreased MBL levels were found in hypothyroid patients.
Endocrinologists at the Medical University of Lodz (Lodz, Poland) tested patients who were divided into two groups of 70 patients with low normal TSH (< 2.5 mIU/L) (Controls), and 25 patients (26.3% of the whole sample examined) with high normal TSH (≥2.5 mIU/L), which were well matched at baseline in terms of age and body mass index (BMI). Nineteen patients were previously diagnosed to be hypothyroid and therefore they were treated with L-thyroxine (25–150 μg daily).
The team measured in serum hormones (TSH, FT4, FT3), thyroid antibodies (i.e. thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb) and thyrotropin receptor antibodies (TSHRAb)), among other laboratory parameters (such as total cholesterol, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), HDLC/cholesterol ratio, triglycerides (TGs), glucose, C-reactive protein (CRP), iron, and lipid peroxidation. Serum concentration of MBL was measured by an enzyme-linked immunosorbent assay (ELISA) using a commercial human MBL ELISA kit (RayBiotech, Inc, Peachtree Corners, GA, USA), with a detection threshold of 0.03 ng/mL. The readings were performed on a Synergy H1 microplate reader (BioTek, Winooski, VT, USA) with a wavelength of 450 nm.
The investigators found that serum MBL level was lower in women with TSH ≥ 2.5 mIU/L than with TSH < 2.5 mIU/L. This association was confirmed by univariate regression analysis. MBL level was significantly lower in patients with abnormally low HDLC/cholesterol ratio and a positive correlation was found between MBL level and HDL/cholesterol ratio. MBL level was not statistically associated with L-thyroxine treatment when evaluated by the univariate logistic regression analysis. MBL level did not correlate with either TPOAb or TgAb.
The authors concluded that in women of reproductive age with normal thyroid tests, lower MBL is associated with high normal TSH and with less favorable lipid profile. Therefore, treatment with L-thyroxine should be considered in women of reproductive age with TSH ≥ 2.5 mIU/l. The study was published on January 3, 2020 in the journal BMC Endocrine Disorders.
Related Links:
Medical University of Lodz
RayBiotech Inc
BioTek
In turn, adverse pregnancy outcomes and infertility may result from hypothyroidism, even in patients with high normal thyroid-stimulating hormone (TSH). An increased MBL blood level was found in hyperthyroid patients while decreased MBL levels were found in hypothyroid patients.
Endocrinologists at the Medical University of Lodz (Lodz, Poland) tested patients who were divided into two groups of 70 patients with low normal TSH (< 2.5 mIU/L) (Controls), and 25 patients (26.3% of the whole sample examined) with high normal TSH (≥2.5 mIU/L), which were well matched at baseline in terms of age and body mass index (BMI). Nineteen patients were previously diagnosed to be hypothyroid and therefore they were treated with L-thyroxine (25–150 μg daily).
The team measured in serum hormones (TSH, FT4, FT3), thyroid antibodies (i.e. thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb) and thyrotropin receptor antibodies (TSHRAb)), among other laboratory parameters (such as total cholesterol, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), HDLC/cholesterol ratio, triglycerides (TGs), glucose, C-reactive protein (CRP), iron, and lipid peroxidation. Serum concentration of MBL was measured by an enzyme-linked immunosorbent assay (ELISA) using a commercial human MBL ELISA kit (RayBiotech, Inc, Peachtree Corners, GA, USA), with a detection threshold of 0.03 ng/mL. The readings were performed on a Synergy H1 microplate reader (BioTek, Winooski, VT, USA) with a wavelength of 450 nm.
The investigators found that serum MBL level was lower in women with TSH ≥ 2.5 mIU/L than with TSH < 2.5 mIU/L. This association was confirmed by univariate regression analysis. MBL level was significantly lower in patients with abnormally low HDLC/cholesterol ratio and a positive correlation was found between MBL level and HDL/cholesterol ratio. MBL level was not statistically associated with L-thyroxine treatment when evaluated by the univariate logistic regression analysis. MBL level did not correlate with either TPOAb or TgAb.
The authors concluded that in women of reproductive age with normal thyroid tests, lower MBL is associated with high normal TSH and with less favorable lipid profile. Therefore, treatment with L-thyroxine should be considered in women of reproductive age with TSH ≥ 2.5 mIU/l. The study was published on January 3, 2020 in the journal BMC Endocrine Disorders.
Related Links:
Medical University of Lodz
RayBiotech Inc
BioTek
Latest Immunology News
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







